Roussel Uclaf SA

As abortion bans take effect nationwide, doctors and advocates have petitioned the FDA over concerns that the Supreme Court’s Dobbs decision leaves a drug used off-label for miscarriage treatment vulnerable to restrictions. The American College of Obstetricians and Gynecologists and 48 other organizations — from the American Civil Liberties Union to the American Medical Association to the Planned Parenthood Federation of America — requested on Tuesday that regulators encourage Danco Laboratories to file an application for its pregnancy termination pill Mifeprex in miscarriage management, and alter the drug’s Risk Evaluation and Mitigation Strategy so it isn’t “unduly burdensome” for that use. Mifeprex, also known as mifepristone, was first developed by the company Roussel Uclaf and marketed in France in the late 1980s. The pill was initially banned in the US, and former President Bill Clinton directed HHS to review and rescind the ban days after taking office. Danco now manufactures Mifeprex in the US. While Mifeprex is only approved to end pregnancy in combination with misoprostol, ACOG writes in the petition that the addition of Mifeprex to misoprostol to treat miscarriage is safe and “may significantly improve treatment efficacy.” However, because of current restrictions, misoprostol is often used alone — and mounting abortion bans won’t make it any easier for patients to access the drug, the petitioners warn. As of Oct. 2, 15 states had enforced total or six-week abortion bans, according to the Guttmacher Institute. Miscarriage is estimated to occur in around a quarter of all pregnancies, according to ACOG, and without proper treatment can result in hemorrhage, sepsis or death. Medical management of miscarriage is “markedly faster” and lowers the risk of needing intervention down the road, compared to an expectant approach, in which patients are only monitored at first, the group said. The federal government previously moved to make medication abortion pills like mifepristone more easily accessible, including by allowing patients to receive the pills by mail. However, advocates are seeking further protections. “Now that the Supreme Court has overturned Roe v. Wade, some states are moving quickly to limit access to drugs that can induce abortion. These efforts have collateral consequences that harm all aspects of reproductive health, including miscarriage management,” the petition states. Danco said in an email to Endpoints News that it has no current plans to file for approval in miscarriage treatment, though that could change. A spokesperson said: “There’s no medical reason to restrict access to an FDA-approved medication,” Kirsten Moore, director of the Expanding Medication Abortion Access Project, said in a news release. “People experiencing miscarriage should have access to the most effective medications and preferred providers without facing barriers or legal risks – it’s that simple.”

Press Release Nicox Appoints Jean-Francois Labbé as Chairman of the Board of DirectorsJuly 29, 2022 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Jean-Francois Labbé, a Board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022. Michele Garufi, who has filled the role ad interim since June 1, 2022, will remain as a Board member.“I am taking up this role at a very exciting time for the company, with Andreas Segerros having joined us recently as Chief Executive Officer and with our first pivotal Phase 3 data on NCX 470 in glaucoma due in November of this year. I look forward to working with Andreas and the Executive Team as we prepare Nicox to continue its development on the back of the NCX 470 clinical data.” said Jean-Francois Labbé, Chairman of Nicox. “On behalf of the Company and the Board of Directors, I would like to express my appreciation for the leadership, dedication and motivation that Michele Garufi brought, both as Chairman and as Chief Executive Officer, since the inception of the company. We are pleased we will continue to benefit from his experience through his position on the Nicox Board.”“The appointment of Jean-Francois Labbé as Chairman of the Board completes the Board and management reorganization which began when I joined the company two months ago. The company is well-positioned to move forward with a strong and experienced executive management and a supportive and effective Board, in a good governance structure.” said Andreas Segerros, Chief Executive Officer of Nicox.Jean-Francois LabbéJean-François Labbé has served as a member of Nicox’ Board of Directors since June 2010 and has been the Chairman of the Audit Committee of Nicox since July 2013. M. Labbé is the Founder and Chief Executive Officer of SpePharm Holding BV, a pan-European specialty pharma company. Prior to founding SpePharm, M. Labbé served as Chief Executive Officer of OTL Pharma SA from 2001 to 2004 and as Chief Operating Officer of ProStrakan UK from 2004 to 2005. He began his career at Roussel Uclaf in 1974, then Hoechst Roussel and HMR, where he served in various positions in Europe, the United States and was a member of the HMR’s Executive Committee before its merger with Aventis in 1999. M. Labbé received an MBA from the Ecole des Hautes Études Commerciales (HEC), Paris, France.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.For more information on Nicox, its products or pipeline, please visit: www.nicox.com.Analyst coverageBryan, Garnier & Co Dylan Van Haaften Paris, FranceEdison Investment Research Pooya Hemami London, UKH.C. Wainwright & Co Yi Chen New York, U.S.Kepler Cheuvreux Arsene Guekam Paris, France The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.NicoxGavin SpencerExecutive Vice President, Chief Business Officer& Head of Corporate Development T +33 (0)4 97 24 53 00communications@nicox.com Investors & MediaUnited States & Europe LifeSci Advisors, LLC Sandya von der Weid T +41 78 680 05 38svonderweid@lifesciadvisors.comForward-Looking StatementsThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2021’ filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is available on Nicox’s website (www.nicox.com)Nicox S.A.Drakkar 2Bât D, 2405 route des DolinesCS 10313, Sophia Antipolis06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24 53 99 Attachment EN_ AnnouncementChairmanJFL_ PR_20220729_F

After a long day of work, you might feel tired or exhilarated. Either way, you are affected by what happened to you in the past. Accelerator magnets are no different. What they went through -- or what went through them, like an electric current -- affects how they will perform in the future. Without understanding a magnet's past, researchers might need to fully reset them before starting a new experiment, a process that can take 10 or 15 minutes. Some accelerators have hundreds of magnets, and the process can quickly become time-consuming and costly. After a long day of work, you might feel tired or exhilarated. Either way, you are affected by what happened to you in the past. Accelerator magnets are no different. What they went through -- or what went through them, like an electric current -- affects how they will perform in the future. Without understanding a magnet's past, researchers might need to fully reset them before starting a new experiment, a process that can take 10 or 15 minutes. Some accelerators have hundreds of magnets, and the process can quickly become time-consuming and costly. Now a team of researchers from the Department of Energy's SLAC National Accelerator Laboratory and other institutions have developed a powerful mathematical technique that uses concepts from machine learning to model a magnet's previous states and make predictions about future states. This new approach eliminates the need to reset the magnets and results in improvements in accelerator performance immediately. "Our technique fundamentally changes how we predict magnetic fields inside accelerators, which could improve the performance of accelerators across the world," SLAC associate scientist Ryan Roussel said. "If the history of a magnet isn't well-known, it will be difficult to make future control decisions to create the specific beam that you need for an experiment." The team's model looks at an important property of magnets known as hysteresis, which can be thought of as residual, or leftover, magnetism. Hysteresis is like the leftover hot water in your shower pipes after you have turned the hot water off. Your shower will not immediately become cold -- the hot water that is left in the pipes must flow out of the showerhead before only cold water is left. "Hysteresis makes tuning magnets challenging," SLAC associate scientist Auralee Edelen said. "The same settings in a magnet that resulted in one beam size yesterday might result in a different beam size today due to the effect of hysteresis." The team's new model removes the need to reset magnets as often and can enable both machine operators and automated tuning algorithms to quickly see their present state, making what was once invisible visible, Edelen said. Ten years ago, many accelerators did not need to consider sensitivity to hysteresis errors, but with more precise facilities like SLAC's LCLS-II coming online, predicting residual magnetism is more critical than ever, Roussel said. The hysteresis model could also help smaller accelerator facilities, which might not have as many researchers and engineers to reset magnets, run higher-precision experiments. The team hopes to implement the method across a full set of magnets at an accelerator facility and demonstrate an improvement in predictive accuracy on an operational accelerator. This research was supported by the U.S. Department of Energy's Office of Basic Energy Sciences. The SLAC Metrology group and the Advanced Photon Source also supported this work.